FORUS Therapeutics is thrilled to welcome Jagroop Dhaliwal, to the department of Medical and Scientific Affairs as an Intern through the Pharmaceutical & Healthcare Management and Innovation graduate program at Queen’s University. Jagroop has a Ph.D. in...

FORUS Therapeutics is thrilled to announce Elaine Lai PharmD, is joining our team as Associate Product and Patient Support Manager. Elaine has already made significant contributions to the FORUS Mission and Vision over the past year, during her internship through the...

(TORONTO, Ontario) October 25, 2022 ­– A big thank you to the TSX/TSXV for hosting the Life Science Investor Day forum in downtown Toronto on Oct 25, 2022, and to the sponsors Life Sciences Ontario, MNP, NATIONAL, TORYS LLP. FORUS Therapeutics was proud to be a...

September is a Blood Cancer Awareness Month, a time to raise awareness and understanding of blood cancers and recognize the patients impacted by these diseases.  FORUS is proud to serve and support the Canadian blood cancer community by bringing new therapeutic...

(OAKVILLE, Ontario) July 13, 2022 – Very pleased and proud to announce that our ForYOU Patient Support Program is up and actively supporting Canadian patients. Officially launched and enrolling patients in need as of July 4, with the first dispense of XPOVIO in...

(OAKVILLE, Ontario) le 7 juin 2022 – FORUS Therapeutics Inc. (« FORUS »), a le plaisir d'annoncer que le 31 mai 2022, Santé Canada a autorisé la vente de XPOVIO® (selinexor) en association avec le bortézomib et la dexaméthasone pour le traitement des patients adultes...

(Saint-lgnace-de-Stanbridge, Quebec) May 28th, 2022 – FORUS was a proud sponsor and participant in the Défi Cyclo-Myélome.  This is the 10th year of this important event which aims to increase awareness about multiple myeloma and raise funds for the Myeloma Canada...

(TORONTO, Ontario) May 2-3, 2022 ­– FORUS Therapeutics Inc, a Canadian Life Sciences company specialized in developing and commercializing unique and differentiated oncology focused therapies is proud to be participating and presenting at the 2022 Bloom Burton &...

(OAKVILLE, Ontario) February 22, 2022 ­– FORUS Therapeutics, a Canadian biopharmaceutical company dedicated to advancing differentiated, novel medicines for hematologic malignancies and other forms of cancer, today announced it has secured $2.5M CAD in growth capital...

FORUS Therapeutics a le plaisir d’annoncer la nomination de Marie-Josèphe Champagne au poste de liaison médicale scientifiques principale pour le Québec et l’Atlantique.  Marie-Josèphe a plus de 18 ans d’expérience dans l’industrie pharmaceutique dans des rôles...

Despite all the global and local challenges; related and unrelated to the pandemic, 2021 has been a year of tremendous growth, progress and development at FORUS. We are excited about 2022 and look forward to fulfilling our mission by bringing innovative new medicines...

In recognition of this last day of September and the close of Blood Cancer Awareness Month, FORUS Therapeutics Inc. is pleased to announce that Health Canada has accepted for review the New Drug Submission (NDS) for once-weekly XPOVIO® (selinexor) in combination with...